Seattle Genetics is an innovative biotechnology company that is dedicated to developing antibody-based therapies for the treatment of cancer. They are the leaders in the technology designed to use monoclonal antibodies to deliver cell-killing solutions directly to cancer cells. This treatment is used so that healthy cells are not damaged and therefore patients suffer reduced side effects that traditional chemotherapy drugs can cause. They are working to bring other products to the market in addition to antibody-drug conjugates (ADCs).
The first product they have is ADCETRIS®, a new class of ADCs. They are in partnership with Takeda Pharmaceutical Company on the drug. It is approved for use in more than 60 countries currently. It is used in treating CD30-expressing lymphomas, Hodgkin lymphoma, T-cell and B-cell lymphomas. Seattle Genetics has full commercialization rights to ADCETRIS in Canada and the United States. The other countries belong to Takeda.
Seattle Genetics started in 1998. It is located in Bothell, Washington. Their first public offering was in March 2001. Clay Siegall, Ph.D. is the President and Chief Executive Officer and Chairman of the Board of the company. He co-founded the company in 1998. Before that he worked with Bristol-Myers Squibb. He was there from 1991 to 1997. He was with the National Cancer Institute, and the National Institutes of Health from 1988 to 1991. Dr. Siegall is on the Board of Directors of two private biotech companies. He received his B.S in Zoology from the University of Maryland and his Ph.D. in Genetics from George Washington University.